Accordingly, on that date, Mr. Wright resigned from his positions as Chairman of the Board, Director and Chief Executive Officer of the Company, effective upon and subject to the Confirmation Condition.
Accordingly, on that date, Mr. Wright resigned from his positions as Chairman of the Board, Director and Chief Executive Officer of the Company, effective upon and subject to the Confirmation Condition.
Jamie Siminoff, the Company’s Chief Strategy Officer, mutually agreed that Mr. Siminoff would step down as the Company’s Chief Strategy Officer on December 31, 2024 (the “Siminoff Separation Date”).
On November 13, 2024, in connection with its strategic shift to refocus on its core healthcare business, Masimo Corporation (the “ Company ”) terminated the employment of Tao Levy, the Company’s Executive Vice President, Business Development.
Departed
John C. Lee, Jr.
President and Chief Executive Officer
OLD DOMINION ELECTRIC COOPERATIVE
Effective
2025-02-01
Successor
Christopher F. Cosby
Filed
November 18, 2024, 6:59 PM ET
On November 12, 2024, John C. Lee, Jr. gave notice of his resignation as President and Chief Executive Officer ("CEO") of Old Dominion Electric Cooperative ("ODEC"), effective February 1, 2025.
On November 14, 2024, Ann Taylor notified Terns Pharmaceuticals, Inc. (the “Company”) of her resignation from the Company’s Board of Directors (the “Board”), effective as of November 18, 2024.
On November 12, 2024, Steve Richards, the Company’s Chief Executive Officer (“CEO”), announced his retirement as Chief Executive Officer of the Company, effective December 2, 2024.
On November 15, 2024, Gregory M. Share informed the Board of Directors (the “Board”) of Runway Growth Finance Corp., a Maryland corporation (the “Company”), of his intent to resign as a director of the Company.
On November 15, 2024, Genesis Energy L.P. (the “Company”) announced that Robert V. Deere, the Company’s Chief Administrative Officer, intends to retire from his position at the Company effective December 31, 2024.
Departed
Timothy Tyson
Director
Syros Pharmaceuticals, Inc.
Effective
2024-11-15
Filed
November 18, 2024, 6:59 PM ET
On November 15, 2024, Srinivas Akkaraju, M.D., Ph.D., Deborah Dunsire, M.D., S. Gail Eckhardt, M.D., Timonthy Tyson, and Richard Young, Ph.D., each notified the Board of Directors of such director’s resignation from the Board of Directors and all committees or subcommittees thereof, effective immediately.
Departed
David Roth
Chief Medical Officer
Syros Pharmaceuticals, Inc.
Effective
2024-11-22
Filed
November 18, 2024, 6:59 PM ET
On November 14, 2024, in connection with the reduction in workforce, the Company notified each of Conley Chee, the Company’s President and Chief Executive Officer, Jason Haas, the Company’s Chief Financial Officer, and Dr. David Roth, the Company’s Chief Medical Officer, that the employment of such officers with the Company will terminate without cause, effective as of November 22, 2024.
Departed
S. Gail Eckhardt
Director
Syros Pharmaceuticals, Inc.
Effective
2024-11-15
Filed
November 18, 2024, 6:59 PM ET
On November 15, 2024, Srinivas Akkaraju, M.D., Ph.D., Deborah Dunsire, M.D., S. Gail Eckhardt, M.D., Timonthy Tyson, and Richard Young, Ph.D., each notified the Board of Directors of such director’s resignation from the Board of Directors and all committees or subcommittees thereof, effective immediately.
Departed
Conley Chee
Director
Syros Pharmaceuticals, Inc.
Effective
2024-11-22
Filed
November 18, 2024, 6:59 PM ET
In addition, Mr. Chee resigned from the Board of Directors and all committees or subcommittees thereof, effective upon his termination of employment on November 22, 2024.
Departed
Deborah Dunsire
Director
Syros Pharmaceuticals, Inc.
Effective
2024-11-15
Filed
November 18, 2024, 6:59 PM ET
On November 15, 2024, Srinivas Akkaraju, M.D., Ph.D., Deborah Dunsire, M.D., S. Gail Eckhardt, M.D., Timonthy Tyson, and Richard Young, Ph.D., each notified the Board of Directors of such director’s resignation from the Board of Directors and all committees or subcommittees thereof, effective immediately.
Departed
Conley Chee
President and Chief Executive Officer
Syros Pharmaceuticals, Inc.
Effective
2024-11-22
Successor
Gerald Quirk
Filed
November 18, 2024, 6:59 PM ET
On November 14, 2024, in connection with the reduction in workforce, the Company notified each of Conley Chee, the Company’s President and Chief Executive Officer, Jason Haas, the Company’s Chief Financial Officer, and Dr. David Roth, the Company’s Chief Medical Officer, that the employment of such officers with the Company will terminate without cause, effective as of November 22, 2024.
Departed
Srinivas Akkaraju
Director
Syros Pharmaceuticals, Inc.
Effective
2024-11-15
Filed
November 18, 2024, 6:59 PM ET
On November 15, 2024, Srinivas Akkaraju, M.D., Ph.D., Deborah Dunsire, M.D., S. Gail Eckhardt, M.D., Timonthy Tyson, and Richard Young, Ph.D., each notified the Board of Directors of such director’s resignation from the Board of Directors and all committees or subcommittees thereof, effective immediately.
Departed
Andrew M. Oh
Director
Syros Pharmaceuticals, Inc.
Effective
2024-11-12
Filed
November 18, 2024, 6:59 PM ET
On November 12, 2024, Andrew M. Oh notified the Board of Directors of the Company of his resignation from the Board of Directors and all committees or subcommittees thereof, effective immediately.
Departed
Jason Haas
Chief Financial Officer
Syros Pharmaceuticals, Inc.
Effective
2024-11-22
Successor
Gerald Quirk
Filed
November 18, 2024, 6:59 PM ET
On November 14, 2024, in connection with the reduction in workforce, the Company notified each of Conley Chee, the Company’s President and Chief Executive Officer, Jason Haas, the Company’s Chief Financial Officer, and Dr. David Roth, the Company’s Chief Medical Officer, that the employment of such officers with the Company will terminate without cause, effective as of November 22, 2024.
Departed
Richard Young
Director
Syros Pharmaceuticals, Inc.
Effective
2024-11-15
Filed
November 18, 2024, 6:59 PM ET
On November 15, 2024, Srinivas Akkaraju, M.D., Ph.D., Deborah Dunsire, M.D., S. Gail Eckhardt, M.D., Timonthy Tyson, and Richard Young, Ph.D., each notified the Board of Directors of such director’s resignation from the Board of Directors and all committees or subcommittees thereof, effective immediately.
Steven P. Rasche, the Company’s current Executive Vice President and Chief Financial Officer and Chief Accounting Officer, has announced his retirement and will continue with the Company as Senior Adviser from January 1, 2025 until his retirement on April 1, 2025.
Departed
Steven P. Rasche
Executive Vice President and Chief Financial Officer
Steven P. Rasche, the Company’s current Executive Vice President and Chief Financial Officer and Chief Accounting Officer, has announced his retirement and will continue with the Company as Senior Adviser from January 1, 2025 until his retirement on April 1, 2025.
Steven P. Rasche, the Company’s current Executive Vice President and Chief Financial Officer and Chief Accounting Officer, has announced his retirement and will continue with the Company as Senior Adviser from January 1, 2025 until his retirement on April 1, 2025.
Departed
Anthony S. Chan
Chief Financial Officer
SHARING SERVICES GLOBAL Corp
Effective
2024-11-14
Filed
November 18, 2024, 6:59 PM ET
On November 14, 2024, Anthony S. Chan ceased to be employed by Sharing Services Global Corporation (the “Company”) or any of its subsidiaries.
to replace Mark DiSiena who’s resignation from his position as Chief Financial Officer was effective November 15, 2024.
Departed
Michaela Griggs
Director
Guardion Health Sciences, Inc.
Effective
2024-11-14
Filed
November 18, 2024, 6:59 PM ET
Effective as of November 14, 2024, Michaela Griggs and Don Gagliano resigned from the Board of the Company
Departed
Don Gagliano
Director
Guardion Health Sciences, Inc.
Effective
2024-11-14
Filed
November 18, 2024, 6:59 PM ET
Effective as of November 14, 2024, Michaela Griggs and Don Gagliano resigned from the Board of the Company
Departed
Mark Castaneda
Director
Gold Flora Corp.
Effective
2024-11-30
Filed
November 18, 2024, 6:59 PM ET
On November 15, 2024, Mark Castaneda notified the Board of Directors (the “Board”) of Gold Flora Corporation (the “Company”) that he will resign as a member of the Board and its committees, effective as of November 30, 2024.
On November 14, 2024, Gregory S. Lovins, Senior Vice President and Chief Financial Officer of Avery Dennison Corporation (the "Company"), began a medical leave of absence.
Departed
Jeffrey S. Berkes
President and Chief Operating Officer
Federal Realty OP LP
Effective
2024-12-31
Filed
November 15, 2024, 6:59 PM ET
On November 15, 2024, Federal Realty Investment Trust (the “Company”) reported that Jeffrey S. Berkes, the Company’s President and Chief Operating Officer, will depart from the Company effective as of December 31, 2024.
On November 14, 2024, Thomas M. White, the Chairman of the Board of Directors (the "Board") of Sterling Infrastructure, Inc. (the "Company"), notified the Company of his intention to retire from the Board effective December 31, 2024.
On November 12, 2024, Matthew D’Ambrosio resigned as a member of the board of directors (the “Board”) of BrightSpring Health Services, Inc. (the “Company”), the Compensation Committee of the Board, and the Quality, Compliance, and Governance Committee of the Board, effective as of November 12, 2024.
Departed
Wayne E. Hardesty
Director
PISMO COAST VILLAGE INC
Effective
2024-09-17
Successor
Kim Dougherty
Filed
November 15, 2024, 6:59 PM ET
the resignation of Wayne E. Hardesty at the Pismo Coast Village Board meeting held on September 17, 2024.
Departed
Michael Breininger
principal financial officer and principal accounting officer
Michael Breininger, the Company’s Corporate Controller, will no longer serve as the principal financial officer and principal accounting officer of the Company.
On November 13, 2024 (the “Termination Date”), the Company terminated the employment of Mina Pastagia, M.D. (“Dr. Pastagia”), Chief Medical Officer of the Company, effective as of the close of business on the Termination Date.
On November 12, 2024, James Murphy resigned as the Company’s Interim Chief Financial Officer.
Departed
George L. Ball
director and Executive Co-Chairman
Tectonic Financial, Inc.
Effective
2024-12-31
Successor
Darrell W. Cain
Filed
November 15, 2024, 6:59 PM ET
Mr. George L. Ball, a director and Executive Co-Chairman of the Company, TBI and the Bank, notified the Boards of his decision to retire from the Boards and as Executive Co-Chairman of the Company, TBI and the Bank, effective December 31, 2024.
Departed
Daniel C. Wicker
director
Tectonic Financial, Inc.
Effective
2024-12-31
Filed
November 15, 2024, 6:59 PM ET
Mr. Daniel C. Wicker, a director of each of Tectonic Financial, Inc. (the “Company”), the Company’s wholly owned subsidiary, T Bancshares, Inc. (“TBI”), and TBI’s wholly owned subsidiary, T Bank, National Association (the “Bank”), notified the Boards of Directors of the Company, TBI and the Bank (collectively, the “Boards”) of his decision to retire from the Boards effective December 31, 2024.
On November 13, 2024, Terry Lee Brubaker gave notice that he will be retiring as the Chief Operating Officer of Gladstone Capital Corporation (the “Company”) effective December 2, 2024.
On November 13, 2024, Terry Lee Brubaker gave notice that he will be retiring as the Chief Operating Officer of Gladstone Commercial Corporation (the “Company”) effective December 2, 2024.
On November 13, 2024, Terry Lee Brubaker gave notice that he will be retiring as the Chief Operating Officer of Gladstone Land Corporation (the “Company”) effective December 2, 2024.
On November 13, 2024, Terry Lee Brubaker gave notice that he will be retiring as the Chief Operating Officer of Gladstone Investment Corporation (the “Company”) effective December 2, 2024.
Departed
Michael J. Grau
Executive Vice President and Chief Financial Officer
On November 13, 2024, Madison Square Garden Entertainment Corp. (the “Company”) and Michael J. Grau, the Company’s Executive Vice President and Chief Financial Officer, agreed that he will be leaving the Company, and effective November 20, 2024, will cease to be Chief Financial Officer.
Departed
Kevin Myers
member of the Board of Directors
AiAdvertising, Inc.
Effective
2024-11-08
Filed
November 15, 2024, 6:59 PM ET
Pursuant to the terms of Mr. Myers’ employment agreement, upon termination, Mr. Myers is deemed to have resigned as a member of the Board of Directors of the Company.
Departed
Kevin Myers
Chief Marketing Officer
AiAdvertising, Inc.
Effective
2024-11-08
Filed
November 15, 2024, 6:59 PM ET
Kevin Myers was terminated as Chief Marketing Officer of AiAdvertising, Inc. (the “Company”).
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.